Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Commissions do not affect our editors' opinions or evaluations. Employees wearing custom T-shirts in-store or at events will promote your brand. You can also give customized T-shirts as ...

Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close. Visa, Netflix, Merck and Hovnanian are included in this Analyst Blog ...

Tamaqua Area School District fourth graders spent a recent day performing experiments inside a mobile lab that visited ...

Long-sleeved T-shirts are an underrated wardrobe staple. As stylist and fashion designer Jordan Page of @veryadvanced points out, the humble long-sleeved tee can look “classier than short ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Belen Garijo took charge of German drug-to-semiconductor group Merck KGaA with the tailwind of the Covid pandemic, propelling the stock to an all-time high in 2021. Since then, the shares have ...

Merck (NYSE:MRK) announced Wednesday that a Phase 3 trial designed to test its anti-PD-1 therapy Keytruda (pembrolizumab) as part of a combination regimen in patients with a type of colorectal ...

Merck (MRK) closed the latest trading day at $113.09, indicating a -1.43% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0. ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...